Introduction
Prostate cancer remains the most common malignancy among elderly men and is the second leading malignancy in the Western World [5] with steadily increasing incidence over the last decade.
Between 2000 and 2050, the number of elderly men affected by prostate cancer is expected to increase 4-fold worldwide [5] . All this leads to a healthcare challenge in terms of radical treatment, in particular surgery in elderly men with good performance status. Current practice of radical treatment for localized prostate cancer is guided by expert guidelines, recommending potentially curative therapy for whose with life expectancy of at least 10 years [1, 2] . Guidelines also stipulate men with limited life expectancy are more likely to die from health conditions other than prostate cancer, and are best managed conservatively as radical treatment may impair their quality of life.
This approach may deprive survival advantage in men older than 70 years, especially with good performance status [3] . This is increasingly realized in the presence of minimally invasive surgery (laparoscopic prostatectomy [LRP] , with or without assistance of robot), with demonstrated improved perioperative morbidity and outcomes [4] . Thus, accepted 10-year rule-a common practice among urologists and radiation oncologists may need a re-visiting [6, 7] . However, aging is a highly individualized, multidimensional process where chronologic age does not always predict the physiologic decline in an individual because, in part, of the effect of comorbidity [9] . Bearing this in mind, there is a need for an approach to extend indications of surgical treatment in selected group of men more than 70 years of age.
Evidence from a recent study suggests that in age-stratified random sample of 347 men from a cohort of patients with newly diagnosed prostate cancer in the Ontario Cancer Registry, several clinical factors can influence treatment options [6] . Patients who were younger than 60 years were more likely to receive radical prostatectomy than radiation therapy or no therapy. Men between 60 and 69 years of age were more likely to receive radiation therapy than radical prostatectomy. Men between 70 and 79 years were most likely to receive conservative therapy such as hormone therapy, and nearly all men over 80 years received no therapy. The decreased likelihood of receiving curative therapy is correlated with patient age, Charlson index score and tumor stage [6] .
The above observation is further supported by reported literature from others. Older men have been shown to receive potentially curative therapy (radical prostatectomy or radiotherapy) less often than younger men. Radical prostatectomy is preferred treatment in men younger than 70 years, whereas radiation therapy is applied predominantly in patients older than 70 years [6] [7] [8] .
Conservative therapy such as watchful waiting or androgen deprivation by luteinizing hormonereleasing hormone analogs is preferentially applied in men older than 80 years.
However, a judicious decisions needs to be made considering age, clinical stage, PSA level, histological grade, and comorbidities. These should be carefully balanced against the survival advantage before making a treatment decision [8] .
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In our centre, we have been offering radical surgery in high risk patients (PSA ≥ 20; Gleason score ≥ 8 and more, ≥cT2c disease) based on a careful assessment and discussions in tumour boards (multidisciplinary teams). We aim to compare the oncological and functional outcomes in elderly men over 70 years diagnosed with high-risk prostate cancer treated with radical therapy (surgery and radiotherapy).
Patients and Methods
The study had Caldecott Institutional Approval (Caldicott/CSAppGN021211 [9] . Study data was collected using a validated record-linkage methodology using the CHI number as described by us previously [10, 11] .
Record linkage technique brings together two or more records relating to the same individual All LRP at our institution were performed by one surgeon (GN). Extended pelvic lymphadenectomy was performed on all patients as described before [12] . All pathological RP specimens were reviewed by a senior Consultant Uropathologists (SL) and discussed in multidisciplinary team meetings to record proper staging including discussion of adjuvant treatment (radiotherapy or hormones)
Demographic and clinical data were collected prospectively from consecutive patients and entered into a comprehensive electronic database such as our (Integrated Clinical Environment). Variables included the following: age, PSA before treatment, PSA post-treatment, cancer stage, Gleason score, and co-morbidities.
Oncological outcomes
The primary outcome was the incidence of biochemical recurrence. This was defined as detectable PSA (>0.2 ug/L) in at least 2 consecutive measurements for men treated by LRP [13] . After primary 7 radical radiotherapy or neoadjuvant hormonal treatment and radiotherapy biochemical recurrence was defined as a consecutive PSA increase > 2 ng/mL higher than the PSA nadir value [13] . Positive surgical margins and the need for adjuvant treatment were recorded. Secondary outcomes being functional outcome and perioperative morbidity.
Functional outcomes

Radiation induced proctitis was graded according the European Organization for Research and
Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) grading system of radiation proctitis [14] ( Table 1 ). The grading classification was used by two members of the research team (AA and CP) to rate the severity of proctitis for each patient within the study. Inter-rater reliability was assessed using the Kappa statistic (Kappa=0.809 with p<0.001) and was found to have substantial agreement [15] .
LRP patients were given the self-administered International Consultation Incontinence
Questionnaire (ICIQ-UI, see supplementary information for questionnaire) [16] at 3, 6, 9 and 12 months post-surgery. For the purpose of this study continence is defined as using no pad or a safety pad [17] in a 24 hour period.
Statistical Analysis
Data were double-entered into the Statistical Package for Social Sciences (SPSS, version 21). Pearson product moment correlation coefficients, paired sample t-tests, Chi-squared, Kruskal-Wallis H test, and Mann-Whitney U test were used. Biochemical recurrence rates were obtained by using the principles of Kaplan-Meier analysis, the Log-Rank, Breslow and the Tarone-Ware tests. Statistical significance was defined as p <0.05.
RESULTS
Of the 338 patients, 117 were treated with radical radiotherapy alone, 167 received neo-adjuvant hormone therapy and radiotherapy, and 54 LRP ( (Figure 1 ), leg ischemia, high Co2 retention, and two men experienced sepsis.
The majority of men stayed in hospital for two nights post LRP and 91% of men were continent by 12 months post-surgery. Two patients had rectal injury; which was identified and repaired during the surgery (histopathology of one patient with rectal mucosa removed with the prostatic specimen, see There was a significant difference in the PSA level between the treatment modalities H(2) = 116.6 , p<.001. A bonferroni correction was applied and so all effects are reported at a .0167 level of significance. PSA levels following radical treatment was significantly lower for men treated by LRP (U = 39.5, p<.000) when compared to RT and RT and HT. However, PSA levels following radical treatment was significantly lower for men treated with RT and HT (U = 8575, p= .011) compared to RT alone, see Figure 3 . The results from the cox proportional hazard analyses χ Table 2 .
The log rank test was performed to determine if there were differences in the biochemical recurrence distribution among the three groups: RT, RT and HT and LRP modalities. The biochemical recurrence distributions for the three groups were statistically significantly different, χ 2 (2) = 21.567, p=0.000 (Figure 2 ).
Discussion
The current study set out to compare the early oncological and functional outcomes in elderly men over 70 years diagnosed with high-risk prostate cancer treated with radical therapy. This study has several important findings. First, LRP with extended lymph node dissection is feasible and acceptable in elderly (≥70years) men with high risk prostate cancer. Evidence acknowledges that elderly men opting for LRP are more likely to have high risk tumour and advanced pathological stages, thus justifying a more aggressive approach in this patient population [18] . Those with biochemical recurrences could potentially be offered salvage treatment options, although numbers are small.
In contemporary practice, however, few men aged 70 years or older undergo curative therapy for high-risk prostate cancer. Compared with observation alone, curative treatment (surgery or radiation therapy) has been shown to improve survival in men aged 65-80 years with low-or intermediate-risk prostate cancer (Gleason score <7) [19] . However, in their retrospective series high-risk patients were not included in the analysis but data acknowledges that men older than 70 years may benefit from curative therapy who have high risk disease prostate cancer [18] .
In high-risk prostate cancer, radical prostatectomy has been effective in oncological control. A large number of patients are cured with surgery alone. Data from a study of biochemical recurrence-free survival showed that 40% of patients had no evidence of disease 10 years after surgery for high-risk cancer [20, 21] . To date, we don't have trial data comparing radical prostatectomy with radiation therapy, so no formal conclusions can be drawn, or indeed the overall benefits for senior men over 70 years with high risk prostate cancer remains little known [22] . But here, we present the first study which compares the incidence of biochemical recurrence across three treatment modalities in high risk prostate cancer in older men. Our findings identify the overall incidence of biochemical recurrence was low 16.7% in the LRP group, compared to RT 51.3% and RT and HT 30.5%, KaplanMeier analysis P<0.000 over a 3 years of follow-up. Follow-up, however remains short and it would be interesting to find out long-term outcome of this cohort.
Radiotherapy is standard treatment for localised prostate cancer and is often combined with hormone treatment to prevent androgen stimulation of prostate cancer. Hormone therapy carries significant morbidity [23] and can only be justified in the radical treatment of localized disease if it can be balanced against a significant gain in disease control and survival. A recent systematic review [24] outlines evidence that the use of combined treatment of androgen deprivation therapy and radiotherapy for intermediate and high-risk localised and locally advanced prostate cancer.
Noteworthy, the patients in our series who underwent RT treatment alone had the underpinning clinical rationale for this practice as the evidence to support the usage of combination of HT and RT was still in its infancy, at that time. However, our findings are in keeping with favorable outcome following the usage of combination HT and RT versus RT alone, based on the findings of the incidence biochemical recurrence over time [24] . In clinical practice the optimal timing, duration, formulation and the management of side-effects of combination HT and RT remain important questions for further research [24] We acknowledge that using the ICIQ-UI evaluation is the gold standard for evaluating patient's health status [25] and controlling for variations in surgical ability and skill [26] was a strength to this study's methodology. The mean duration of hospital stay was 2 days (1-35 days) and similar to other centres [27, 28] . Using the continence definition of 0-1 pads our data showed that LRP can offer good functional outcome with approximately 91% of men returning to baseline continence function by 12 months, and this is similar to data published elsewhere [29] . In contrast, in a prospective study of LRP at 1 year identified that only 60% of men were continent [26] .
The primary goal of radical prostatectomy is cancer control or eradication for patient survival.
Prediction of LRP long-term oncological outcomes are linked to many established clinical factors:
preoperative prostate specific antigen (PSA), clinical and pathologic staging, Gleason grade, seminal vesicle invasion, lymph node invasion, and positive surgical margins [30] . Our study has demonstrated good oncological outcome in this patient group with 84.8% biochemical recurrencefree survival at 37 months comparable with existing data [31] .
The single-surgeon design is advantageous to the study methodology as all of the patients received the same postoperative care and counselling. This allowed for a more critical comparison of oncological and functional outcomes following LRP over time. Furthermore, the data in our study was gathered prospectively by third party and assessed without involvement of surgeon to avoid recall and reporting bias. A further strength to this study was the use of a validated standardised questionnaire, the ICIQ-UI, where by other available studies have used interviews or non-validated questionnaires [32, 33] . There are several limitations to our prospective longitudinal observational study. We did not use validated questionnaires to assess erectile dysfunction as most of these men opted for wide local excision in view of high risk disease or for radical radiotherapy with hormones.
Moreover, there is a lack of randomization to treatment allocation which may introduce selection bias, however study represents a more of "real life" clinical practice. Finally, we acknowledge that the results should be replicated in a larger sample size with a longer follow-up duration. Despite 12 these limitations, the results provide new emergent information to inform the clinical management of elderly men with high risk prostate cancer.
Conclusion
High risk prostate cancer treated by radical surgery demonstrated improved early oncological and functional outcomes compared to radiotherapy with or without hormones. Radical prostatectomy was safe and feasible with good functional outcome, and these findings should inform future treatment decisions in men aged more than 70 years with high risk disease and good performance status. 
